Investor Presentation

Biosimilar mAbs market opportunities expanding Global Biosimilar Market Outlook¹ $20B $30B 2022 2025 $60B 2030 97 programs in development adalimumab LUCENTIS RANIBIZUMAB INJECTION "Top 6" mAbs with launched biosimilars AVASTIN bevacizumab ROMINEECTION FOR USE Remicade INFLIXIMAB Herceptin trastuzumab 21 mg/mL INJECTION FOR INTRAVENOUS USE Rituxan Rituximab Total Sales R REPLIGEN ¹Amgen Biosimilars 2022 Trend Report. 1st approvals: 2006 EU, 2015 US 2021 Sales $20.7B $3.6B $3.4B $3.2B $2.9B $2.8B $36.6B 22 additional approvals pending for 1H-23 2022 Sales $21.2B $2.9B $2.4B $2.3B $2.4B $2.1B $33.3B US FDA approved biosimilars 8² 2 4 4 5 3 26 approved 15 launched 9

View entire presentation